Alzheimer's Disease Education and Referral Center

PhytoSERMs for Menopause Symptoms and Age-Associated Memory Decline

PhytoSERMs for Menopause Symptoms and Age-Associated Memory Decline

Overall Status: 
Recruiting
Brief Description: 

The purpose of this study is to evaluate the safety and efficacy of a soy-based dietary supplement, phytoSERM (selective estrogen receptor modulator), for hot flashes and age-associated memory loss. PhytoSERMs are plant-derived substances that possess SERM qualities, similar to synthetically manufactured drugs of the same category.

Patient Qualifications: 
Min AgeMax AgeGenderHealthy Volunteers
48 Years
58 Years
Female
No
Inclusion Criteria: 
    • Postmenopausal
    • Vasomotor symptom(s) such as hot flashes
    • Memory complaint
Exclusion Criteria: 
    • History of clinically significant stroke
    • Current evidence or history in past 2 years of epilepsy, seizure, focal brain lesion, head injury with loss of consciousness, or major psychiatric disorder, including psychosis, major depression, bipolar disorder, alcohol or substance abuse
    • Known allergy to soy-derived products
    • Hypersensitivity to estrogens or progestins
Detailed Description: 

None provided.

Locations: 
Map Marker CityStateZip CodeStatusPrimary Contact

Geolocation is 34.0502898, -118.2117257

University of Southern California Keck School of Medicine
Los Angeles
California
90033
Recruiting
Gerson Hernandez
323-442-5775
gersonhe@usc.edu
Lead Sponsor: 
Agency
University of Southern California
Collaborator Sponsor: 
Agency
National Institute on Aging
Facility Investigators: 
NameRoleAffiliation
Lon S. Schneider, MD
Principal Investigator
University of Southern California
Study Contact: 
NamePhoneEmail
Gerson Hernandez, MD
323-442-5775
Nadine Diaz
323-442-5775
Locations
 
 
ClinicalTrials.gov ID 
NCT01723917 (follow link to view full record on ct.gov in new window)
Official Title: 
Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated Memory Decline
Study Start Date: 
July 2012
Study End Date: 
July 2014
Disease Stage: 
Early
Enrollment: 
78